Rhinomed (ASX:RNO) COGS-to-Revenue : 0.20 (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed COGS-to-Revenue?

Rhinomed's Cost of Goods Sold for the six months ended in Jun. 2023 was A$0.80 Mil. Its Revenue for the six months ended in Jun. 2023 was A$4.09 Mil.

Rhinomed's COGS to Revenue for the six months ended in Jun. 2023 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Rhinomed's Gross Margin % for the six months ended in Jun. 2023 was 80.39%.

Rhinomed COGS-to-Revenue Historical Data

The historical data trend for Rhinomed's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed COGS-to-Revenue Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

0.33

0.41

0.29

0.32

0.25

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															0.25	0.36	0.29	0.32	0.20

Rhinomed COGS-to-Revenue Calculation

Rhinomed's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.881	/	7.472
	=	0.25

Rhinomed's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.802	/	4.089
	=	0.20

Rhinomed (ASX:RNO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Rhinomed's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.802 / 4.089
	=	80.39 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Rhinomed COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rhinomed's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines